Konstantinopoulos PA, et al. - Single-agent cabozantinib was evaluated for its efficacy and tolerability in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. Researchers recruited patients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50% clear cell histomorphology, measurable disease, one or two prior regimens and ECOG performance status 0–2 to receive cabozantinib 60 mg orally once daily continuously, in 4-week cycles until disease progression or unacceptable toxicity. They noted no objective responses, however, 3 of 13 patients exhibited progression-free survival ≥ 6 months. Cabozantinib thus demonstrated minimal activity in the second- and third-line treatments of clear cell ovarian, fallopian tube or primary peritoneal carcinoma. Thromboembolism, nausea, vomiting, fatigue, dyspnea, dehydration were the grade ≥3 AEs encountered.